CY1121602T1 - Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της - Google Patents

Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της

Info

Publication number: CY1121602T1
Authority: CY; Cyprus
Prior art keywords: copanalisib; dihydrochloride; kopanlisimpi; dihydrochlorate; composition
Prior art date: 2014-11-07

Application number

CY20191100444T

Other languages

Greek (el)

English (en)

Inventor

Jan Georg PETERS

Philipp Rubenbauer

Daniel Götz

Danja Grossbach

Franz-Josef Mais

Heiko Schirmer

Juergen Stiehl

Kai Lovis

Andreas Lender

Martin Seyfried

Theodor Zweifel

Maurus Marty

Günter Weingärtner

Original Assignee

Bayer Pharma Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-07

Filing date

2019-04-23

Publication date

2020-05-29

2019-04-23 Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft

2020-05-29 Publication of CY1121602T1 publication Critical patent/CY1121602T1/el

Links

239000000543 intermediate Substances 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CY20191100444T 2014-11-07 2019-04-23 Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της CY1121602T1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14192203.9A EP3018127A1 (de)	2014-11-07	2014-11-07	Synthese von Copanlisib sowie dessen Dihydrochloridsalz
PCT/EP2015/075789 WO2016071435A2 (en)	2014-11-07	2015-11-05	Synthesis of copanlisib and its dihydrochloride salt

Publications (1)

Publication Number	Publication Date
CY1121602T1 true CY1121602T1 (el)	2020-05-29

Family

ID=51866061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY20191100444T CY1121602T1 (el)	2014-11-07	2019-04-23	Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της

Country Status (46)

Country	Link
US (1)	US10494372B2 (de)
EP (2)	EP3018127A1 (de)
JP (1)	JP6691115B2 (de)
KR (1)	KR102566834B1 (de)
CN (1)	CN107278204B (de)
AR (1)	AR102570A1 (de)
AU (1)	AU2015341788B2 (de)
BR (1)	BR112017009470B1 (de)
CA (1)	CA2966800C (de)
CL (1)	CL2017001131A1 (de)
CO (1)	CO2017004532A2 (de)
CR (1)	CR20170184A (de)
CU (1)	CU24489B1 (de)
CY (1)	CY1121602T1 (de)
DK (1)	DK3215493T3 (de)
DO (1)	DOP2017000112A (de)
EA (1)	EA035558B1 (de)
EC (1)	ECSP17027755A (de)
ES (1)	ES2721778T3 (de)
HR (1)	HRP20190720T1 (de)
HU (1)	HUE042866T2 (de)
IL (1)	IL251874A0 (de)
JO (1)	JO3644B1 (de)
LT (1)	LT3215493T (de)
MA (1)	MA40895B1 (de)
ME (1)	ME03358B (de)
MX (1)	MX366904B (de)
MY (1)	MY189852A (de)
NI (1)	NI201700054A (de)
NZ (1)	NZ731287A (de)
PE (1)	PE20170897A1 (de)
PH (1)	PH12017500833A1 (de)
PL (1)	PL3215493T3 (de)
PT (1)	PT3215493T (de)
RS (1)	RS58579B1 (de)
SA (1)	SA517381462B1 (de)
SG (1)	SG11201703702RA (de)
SI (1)	SI3215493T1 (de)
SV (1)	SV2017005433A (de)
TN (1)	TN2017000179A1 (de)
TR (1)	TR201905217T4 (de)
TW (1)	TWI697495B (de)
UA (1)	UA122398C2 (de)
UY (1)	UY36392A (de)
WO (1)	WO2016071435A2 (de)
ZA (1)	ZA201703867B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2168583A1 (de)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Verwendungen von substituierten 2,3-Dihydroimidazo[1,2-c]quinazolinen zur Behandlung von Myelom
EP2508525A1 (de)	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituierte 2,3-Dihydroimidazo[1,2-c]chinazolinsalze
UA119537C2 (uk)	2013-04-08	2019-07-10	Байєр Фарма Акцієнгезелльшафт	ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
CA2978830A1 (en)	2015-03-09	2016-09-15	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CA3016584A1 (en)	2016-03-08	2017-09-14	Bayer Pharma Aktiengesellschaft	2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
CA3037626A1 (en)	2016-09-23	2018-03-29	Bayer Pharma Aktiengesellschaft	Combination of pi3k-inhibitors
WO2018215282A1 (en)	2017-05-26	2018-11-29	Bayer Pharma Aktiengesellschaft	Combination of bub1 and pi3k inhibitors
EP3645005A1 (de)	2017-06-28	2020-05-06	Bayer Consumer Care AG	Kombination eines pi3k-hemmers mit einem androgen-rezeptor-antagonisten
EP3498266A1 (de)	2017-12-15	2019-06-19	Bayer Consumer Care AG	Formulierungen von copanlisib
CN111278430A (zh)	2017-09-08	2020-06-12	拜耳制药股份公司	库潘尼西制剂
WO2023139125A1 (en)	2022-01-18	2023-07-27	Synthon B.V.	Improved process for preparation of copanlisib
WO2023218032A1 (en)	2022-05-13	2023-11-16	Synthon B.V.	Solid forms of copanlisib salts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1003580A (en)	1910-08-10	1911-09-19	Remington Typewriter Co	Type-writing machine.
US6221877B1 (en) *	2000-04-12	2001-04-24	Regents Of The University Of California	Substituted 4-phthalimidocarboxanilides as inhibitors of purine salvage phosphoribosyltransferases
IT1319674B1 (it) *	2000-12-01	2003-10-23	Erregierre Spa	Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
TW565582B (en) *	2001-04-13	2003-12-11	Kaneka Corp	Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them
EP1417204B1 (de) *	2001-08-15	2006-01-18	E. I. du Pont de Nemours and Company	Mit heterocyclen ortho-substituierte aryl amide zur bekämpfung wirbelloser schädlinge
AU2003293310B2 (en)	2002-09-30	2010-04-01	Bayer Intellectual Property Gmbh	Fused azole-pyrimidine derivatives
AR064106A1 (es) *	2006-12-05	2009-03-11	Bayer Schering Pharma Ag	Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
JP5620275B2 (ja) *	2008-01-14	2014-11-05	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体類
EP2168583A1 (de)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Verwendungen von substituierten 2,3-Dihydroimidazo[1,2-c]quinazolinen zur Behandlung von Myelom
EP2508525A1 (de) *	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituierte 2,3-Dihydroimidazo[1,2-c]chinazolinsalze
JO3733B1 (ar)	2011-04-05	2021-01-31	Bayer Ip Gmbh	استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
UA119537C2 (uk)	2013-04-08	2019-07-10	Байєр Фарма Акцієнгезелльшафт	ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
JP6499657B2 (ja)	2013-12-03	2019-04-10	バイエルファーマアクチエンゲゼルシャフト	Ｐｉ３ｋ阻害剤の組み合わせ
EP3018131A1 (de) *	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthese von Copanlisib sowie dessen Dihydrochloridsalz
CA2978830A1 (en)	2015-03-09	2016-09-15	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
JP2018512403A (ja)	2015-03-09	2018-05-17	バイエルファーマアクチエンゲゼルシャフト	置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
CA3012951A1 (en)	2016-02-01	2017-08-10	Bayer Pharma Aktiengesellschaft	Copanlisib biomarkers
EP3411497A1 (de)	2016-02-01	2018-12-12	Bayer Pharma Aktiengesellschaft	Copanlisib-biomarker
CA3016584A1 (en)	2016-03-08	2017-09-14	Bayer Pharma Aktiengesellschaft	2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
CA3037626A1 (en)	2016-09-23	2018-03-29	Bayer Pharma Aktiengesellschaft	Combination of pi3k-inhibitors

2014
- 2014-11-07 EP EP14192203.9A patent/EP3018127A1/de not_active Withdrawn
2015
- 2015-11-04 JO JOP/2015/0274A patent/JO3644B1/ar active
- 2015-11-05 MA MA40895A patent/MA40895B1/fr unknown
- 2015-11-05 WO PCT/EP2015/075789 patent/WO2016071435A2/en not_active Ceased
- 2015-11-05 ME MEP-2019-107A patent/ME03358B/de unknown
- 2015-11-05 EA EA201790983A patent/EA035558B1/ru not_active IP Right Cessation
- 2015-11-05 SG SG11201703702RA patent/SG11201703702RA/en unknown
- 2015-11-05 MX MX2017005893A patent/MX366904B/es active IP Right Grant
- 2015-11-05 PL PL15790150T patent/PL3215493T3/pl unknown
- 2015-11-05 CA CA2966800A patent/CA2966800C/en active Active
- 2015-11-05 HR HRP20190720TT patent/HRP20190720T1/hr unknown
- 2015-11-05 ES ES15790150T patent/ES2721778T3/es active Active
- 2015-11-05 KR KR1020177014992A patent/KR102566834B1/ko active Active
- 2015-11-05 BR BR112017009470-3A patent/BR112017009470B1/pt not_active IP Right Cessation
- 2015-11-05 RS RS20190453A patent/RS58579B1/sr unknown
- 2015-11-05 UY UY0001036392A patent/UY36392A/es not_active Application Discontinuation
- 2015-11-05 AU AU2015341788A patent/AU2015341788B2/en not_active Ceased
- 2015-11-05 PT PT15790150T patent/PT3215493T/pt unknown
- 2015-11-05 TR TR2019/05217T patent/TR201905217T4/tr unknown
- 2015-11-05 PE PE2017000818A patent/PE20170897A1/es unknown
- 2015-11-05 DK DK15790150.5T patent/DK3215493T3/da active
- 2015-11-05 CN CN201580072735.8A patent/CN107278204B/zh not_active Expired - Fee Related
- 2015-11-05 TN TN2017000179A patent/TN2017000179A1/en unknown
- 2015-11-05 US US15/524,581 patent/US10494372B2/en active Active
- 2015-11-05 MY MYPI2017701550A patent/MY189852A/en unknown
- 2015-11-05 SI SI201530695T patent/SI3215493T1/sl unknown
- 2015-11-05 HU HUE15790150A patent/HUE042866T2/hu unknown
- 2015-11-05 JP JP2017523881A patent/JP6691115B2/ja not_active Expired - Fee Related
- 2015-11-05 UA UAA201705433A patent/UA122398C2/uk unknown
- 2015-11-05 CR CR20170184A patent/CR20170184A/es unknown
- 2015-11-05 CU CU2017000061A patent/CU24489B1/es unknown
- 2015-11-05 LT LTEP15790150.5T patent/LT3215493T/lt unknown
- 2015-11-05 EP EP15790150.5A patent/EP3215493B1/de active Active
- 2015-11-05 NZ NZ731287A patent/NZ731287A/en not_active IP Right Cessation
- 2015-11-06 AR ARP150103619A patent/AR102570A1/es unknown
- 2015-11-06 TW TW104136742A patent/TWI697495B/zh not_active IP Right Cessation
2017
- 2017-04-24 IL IL251874A patent/IL251874A0/en active IP Right Grant
- 2017-05-04 PH PH12017500833A patent/PH12017500833A1/en unknown
- 2017-05-04 SA SA517381462A patent/SA517381462B1/ar unknown
- 2017-05-05 SV SV2017005433A patent/SV2017005433A/es unknown
- 2017-05-05 CO CONC2017/0004532A patent/CO2017004532A2/es unknown
- 2017-05-05 EC ECIEPI201727755A patent/ECSP17027755A/es unknown
- 2017-05-05 DO DO2017000112A patent/DOP2017000112A/es unknown
- 2017-05-05 CL CL2017001131A patent/CL2017001131A1/es unknown
- 2017-05-05 NI NI201700054A patent/NI201700054A/es unknown
- 2017-06-06 ZA ZA2017/03867A patent/ZA201703867B/en unknown
2019
- 2019-04-23 CY CY20191100444T patent/CY1121602T1/el unknown

Also Published As

Publication number	Publication date
MA40895A (fr)	2017-09-13
MA40895B1 (fr)	2019-07-31
EA035558B1 (ru)	2020-07-07
EP3215493B1 (de)	2019-01-23
HUE042866T2 (hu)	2019-07-29
AR102570A1 (es)	2017-03-08
HRP20190720T1 (hr)	2019-06-14
PE20170897A1 (es)	2017-07-12
NI201700054A (es)	2017-07-17
PH12017500833A1 (en)	2017-10-18
TR201905217T4 (tr)	2019-05-21
HK1245774A1 (zh)	2018-08-31
NZ731287A (en)	2023-01-27
CA2966800A1 (en)	2016-05-12
DK3215493T3 (da)	2019-05-06
WO2016071435A3 (en)	2016-06-30
UA122398C2 (uk)	2020-11-10
ME03358B (de)	2019-10-20
CN107278204B (zh)	2019-12-17
KR20170082563A (ko)	2017-07-14
SA517381462B1 (ar)	2021-01-25
CO2017004532A2 (es)	2017-07-19
TN2017000179A1 (en)	2018-10-19
CU20170061A7 (es)	2017-10-05
PT3215493T (pt)	2019-05-21
AU2015341788A1 (en)	2017-05-18
AU2015341788B2 (en)	2020-01-16
US20180282337A1 (en)	2018-10-04
MX366904B (es)	2019-07-30
BR112017009470B1 (pt)	2022-11-01
CU24489B1 (es)	2020-12-17
CN107278204A (zh)	2017-10-20
CL2017001131A1 (es)	2018-01-19
EP3018127A1 (de)	2016-05-11
BR112017009470A2 (en)	2018-01-02
SG11201703702RA (en)	2017-06-29
JO3644B1 (ar)	2020-08-27
MY189852A (en)	2022-03-14
ZA201703867B (en)	2019-07-31
EP3215493A2 (de)	2017-09-13
CR20170184A (es)	2017-06-20
US10494372B2 (en)	2019-12-03
IL251874A0 (en)	2017-06-29
ECSP17027755A (es)	2017-06-30
SV2017005433A (es)	2018-04-30
MX2017005893A (es)	2017-06-30
KR102566834B1 (ko)	2023-08-16
JP6691115B2 (ja)	2020-04-28
ES2721778T3 (es)	2019-08-05
SI3215493T1 (sl)	2019-05-31
DOP2017000112A (es)	2017-06-15
CA2966800C (en)	2023-02-21
PL3215493T3 (pl)	2019-07-31
UY36392A (es)	2016-06-30
TWI697495B (zh)	2020-07-01
LT3215493T (lt)	2019-04-25
JP2017534631A (ja)	2017-11-24
RS58579B1 (sr)	2019-05-31
WO2016071435A2 (en)	2016-05-12
TW201625634A (zh)	2016-07-16
EA201790983A1 (ru)	2017-10-31

Publication	Publication Date	Title
CY1124215T1 (el)	2022-05-27	Μκ2 αναστολεις και χρησεις αυτων
JOP20200110A1 (ar)	2020-05-07	متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
EA201891211A1 (ru)	2018-12-28	Ингибиторы cxcr2
EA202092435A2 (ru)	2021-02-26	Моноклональные антитела против bcma
MX384201B (es)	2025-03-14	Proceso para la preparacion de treprostinil.
EA201692203A1 (ru)	2017-06-30	Соединения, ингибирующие tank-связывающую киназу
UY36175A (es)	2016-01-29	3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
EA201692219A1 (ru)	2017-05-31	Способы получения противовирусных соединений
BR112016029333A2 (pt)	2017-08-22	síntese de compostos de carbamoilpiridona policíclico
EA201692526A1 (ru)	2017-05-31	Замещенные [1,2,4]триазольные соединения
EA201790983A1 (ru)	2017-10-31	Синтез копанлисиба и его дигидрохлорида
EA201891586A1 (ru)	2018-12-28	Антипролиферативные соединения и их фармацевтические композиции и применения
CR20170005A (es)	2017-05-08	Derivados de insoindolina
ITUA20162445A1 (it)	2017-10-08	Dispositivo di prelievo di articoli.
EA201790982A1 (ru)	2017-10-31	Синтез копанлисиба и его дигидрохлорида
CY1125143T1 (el)	2023-06-09	Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων
CY1120131T1 (el)	2018-12-12	Επαφεας για μια στηλη ανταλλαγης που αποτελειται απο μια διαταξη δομικων επενδυσεων
CR20150417A (es)	2015-09-16	Compuestos de azetidiniloxifenilpirrolidina
CL2017000151A1 (es)	2017-07-28	Derivados de piridona
UA117779C2 (uk)	2018-09-25	Піразини як модулятори gpr6
BR112017019176A2 (pt)	2018-04-24	processos para a preparação de fluorocetolídeos
MX381489B (es)	2025-03-12	Compuesto biciclico y uso del mismo para la inhibicion de suv39h2.
SI3325453T1 (sl)	2021-04-30	Postopki kemijske sinteze substituiranih 10H-fenotiazin-3,7-diaminskih spojin
MX389099B (es)	2025-03-20	Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos.
MX374286B (es)	2025-03-06	Compuestos organolepticos novedosos.